Products
Products Categories
Explore our diverse portfolio of pharmaceutical products, ranging from medications for chronic diseases to breakthrough treatments for rare conditions. With a focus on research and development, we continually seek to expand our product offerings and improve existing therapies to meet the evolving needs of patients worldwide.
Azitropro
Breathese Syrup
Cefpodsafe Dry
Cycloguard Cap
Triprotect
Cycloguard Cap
Azitropro
Breathese Syrup
Cefpodsafe Dry
Cycloguard Cap
Triprotect
Product Approved in Europe / UK
| Molecule Name | Strength | Therapy | Innovator & Brand | Registered Markets |
|---|---|---|---|---|
| Amlodipine Tablets | 5 mg and 10 mg | Antihypertensive | Istin ® | Portugal, Austria, Spain, Ireland, Italy, Poland. |
| Cetirizine dihydrochloride Tablets | 10 mg | Antihistamines | Zirtek® | Portugal and Poland. |
| Levocetirizine dihydrochloride Tablets | 5 MG | Antihistamines | Xyzal® | Germany, Poland, Portugal. |
| Telmisartan Tablets | 20mg,40mg and 80mg | Angiotensin II receptor antagonists | Micardis® | Germany, Belgium, Ireland, Netherland, Portugal. |
| Telmisartan/Amlodipine Tablets | 40mg/5mg 80mg/5mg 40mg/10mg 80mg/10mg |
Antihypertensive | Twynsta® | Hungary |
| Paroxetin Tablets | 20 mg | Selective serotonin reuptake inhibitor (SSRI) | Seroxat® | UK |
| Carbidopa and levodopa Tablets | 25 mg/100 mg 25 mg/250 mg 10 mg/100 mg12.5mg/50 mg |
Antiparkinsonian | Sinemet® | Germany, Ireland and Austria |
PRE-LAUNCH PRODUCTS FOR EUROPE/UK
| Molecule Name | Strength | Therapy | Innovator & Brand | Current Stage |
|---|---|---|---|---|
| Azithromycin Capsules | 250 mg | Antibiotics | Zithromax®(UK) | e CTD dossier is available for new filing. |
| Azithromycin Tablets | 250 mg and 500 mg | Antibiotics | Tromax®(UK) | e CTD dossier is available for new filing. |
| Raloxifene Tablets | 60 mg | Prevention of postmenopausal Osteoporosis | Evista® (Germany) |
e CTD dossier is available for new filing. |
| Telmisartan hydrochlorothiazide Tablets | 40 mg/12.5 mg 80 mg/12.5 mg 80 mg/25 mg |
Antihypertensive | Micardis plus® (Germany) | e CTD dossier is available for new filing. |
| Carbidopa and levodopa ER Tablets | 25 mg/100 mg 50 mg/200 mg |
Antiparkinsonian | Sinemet CR®(UK) | e CTD dossier is available for new filing. |
| Olmesartan medoxomil Tablets | 10 mg 20 mg 40 mg |
Angiotensin II receptor antagonists | Olmetec®(UK) | e CTD dossier is available for new filing |
| Olmesartan + Hydrochlorothiazide Tablets | 20 mg /12.5 mg 20 mg/25 mg 40 mg/12.5 mg 40 mg/25 mg |
Antihypertensive | CoOlmetec® (France) | e CTD dossier is available for new filing |
| Metformin IR Tablets | 500 mg 850 mg 1000 mg |
Type 2 Anti diabetics | Glucophage® (Spain) | e CTD dossier is available for new filing |
| Desloratadine Tablets | 5mg | Antihistamines | Aerius® (Belgium) | eCTD dossier is available for new filing |
| Etoricoxib Tablets | 60 mg 90 mg 120 mg |
NSAIDS | Arcoxia® (Netherland) | eCTD dossier is available for new filing |
DEVELOPMENT PIPELINE FOR EUROPE/UK
| Molecule Name | Strength | Therapy | Innovator & Brand | Current Stage |
|---|---|---|---|---|
| Dimethyl fumarate Capsules | 120 mg and 240 mg | Treatment of multiple sclerosis | Tecfidera®(Bulgaria) | BE Study scheduled in Q125 |
| Clopidogrel Tablets | 75 mg | Antiplatelet | Plavix®(France) | BE Study scheduled in Q125 |
| Hydroxyzine HCl Tablets | 10 mg and 25 mg | Antihistamine with anticholinergic | Atarax® (Germany) | PVB in Q2 2025 |
| Levocetirizine + montelukast Tablets | 5 mg /10 mg | Antihistamines | Montelukast-Singulair (Organon) & Levocetirizine –Zyzal (UCB) from Germany | PVB in Q2 2025 |
| Esomeprazole DR Tablets | 20 mg and 40 mg | Treatment of GERD | Nexium® (UK) | PVB in Q2 2025 |
| Rosuvastatin Tablets | 10 mg,20 mg and 40mg | Antihyperlipidemic | Crestor®(Germany) | e CTD dossier is available by March 25 |
| Escitalopram Oxalate Tablets | 5 mg ,10 and 20 mg | Antidepressants | Cipralex®(Denmark) | e CTD dossier is available by February 25 |
| Valsartan + hydrochlorothiazideTablets | 160 mg/12.5 mg | Antihypertensive | CoDiovan® (Denmark) |
e CTD dossier is available by March 25 |
| Valsartan + Amlodipine Tablets | 160 mg/10 mg | Antihypertensive | Exforge®(Denmark) | e CTD dossier is available by March 25 |
| Linagliptin Tablets | 5 mg | Type 2 antidiabetics | Tradjenta®(EU) | PVB in Q3 2025 |
| Linagliptin + Metformin HCl Tablets | 2.5 mg/500 mg 2.5 mg/850 mg 2.5 mg/1000 mg |
Type 2 antidiabetics | Jentadueto®(EU) | PVB in Q3 2025 |
| Dapagliflozin film coated Tablets | 5 mg and 10 mg | Type 2 antidiabetics | Forxiga® (EU) | PVB in Q3 2025 |
| Dapagliflozin + Metformin hydrochloride Tablets | 2.5 mg/1 gm. 5 mg/500 mg 5 mg/1 gm. 10 mg/500 mg 10 mg/1 gm. |
Type 2 antidiabetics | Xigduo XR® (EU) | PVB in Q3 2025 |
| Empagliflozin Tablets | 10 mg and 25 mg | Type 2 antidiabetics | Jardiance® (EU) | PVB in Q3 2025 |
| Empagliflozin + Metformin hydrochloride Tablets | 5 mg/500 mg 5 mg/1 mg 12.5 mg/500 mg 12.5 mg/1 gm. |
Type 2 antidiabetics | Synjardy® (EU) | PVB in Q3 2025 |